Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.68 |
| ▸ | CPA1 | P15085 | 5/20 | 0.57 |
| ▸ | CPA3 | P15088 | 2/20 | 0.57 |
| ▸ | CPB1 | P15086 | 1/20 | 0.57 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101857 | 0.85 | TSHR (0.60) | KMOCPA1CPA3CPB1CPB2 | |
| SCHEMBL6674722 | 0.84 | KMO (0.57) | KMOPPARGPPARA | |
| SCHEMBL3104186 | 0.82 | TSHR (0.75) | KMOCPA1CPA3CPB1CPB2 | |
| SCHEMBL7315538 | 0.82 | TSHR (0.75) | KMOCPA1CPA3CPB1CPB2 | |
| SCHEMBL6671105 | 0.82 | KMO (0.54) | KMOPTPN1PPARGPPARA | |
| SCHEMBL727440 | 0.81 | KMO (1.00) | KMOCPA1CPA3CPB1CPB2 | |
| SCHEMBL728320 | 0.81 | KMO (1.00) | KMOCPA1CPA3CPB1CPB2 | |
| SCHEMBL3667472 | 0.81 | KMO (1.00) | KMOCPA1CPA3CPB1CPB2 | |
| SCHEMBL2347491 | 0.79 | KMO (0.63) | KMOCPA1CPA3CPB1CPB2 | |
| SCHEMBL3664996 | 0.79 | KMO (0.63) | KMOCPA1CPA3CPB1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897644-B2 | Antiinflammatory agents; analgesics | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-03-01 | — | — | US | claimed |
| US-20100273872-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH IMMUNOLOGICAL DISORDERS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-10-28 | — | — | US | claimed |
| EP-2214659-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH IMMUNOLOGICAL DISORDERS | Merck Patent GmbH (DE) | 2010-08-11 | — | — | EP | claimed |
| WO-2009071161-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH IMMUNOLOGICAL DISORDERS | MERCK PATENT GMBH (DE) | 2009-06-11 | — | — | WO | claimed |
| EP-1450780-B1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF INFLAMMATION | MERCK PATENT GMBH (DE) | 2007-03-07 | — | — | EP | claimed |
| EP-1448181-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF METFORMIN AND A 4-OXOBUTANOIC ACID, AND THE USE THEREOF FOR TREATING DIABETES | MERCK PATENT GMBH (DE) | 2006-05-31 | — | — | EP | claimed |
| CN-1633304-A | Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes | MERCK PATENT GMBH (DE) | 2005-06-29 | — | — | CN | claimed |
| US-20050085489-A1 | Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes | MERCK PATENT GMBH (DE) | 2005-04-21 | — | — | US | claimed |
| US-20050070553-A1 | Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes | MERCK PATENT GMBH (DE) | 2005-03-31 | — | — | US | claimed |
| CN-1599608-A | Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes | MERCK PATENT GMBH (DE) | 2005-03-23 | — | — | CN | claimed |
| US-20050014768-A1 | Use of 4-oxobutanoic acid derivatives in the treatment of inflammation | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| EP-1463503-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLITAZONE AND A 4-OXOBUTANOIC ACID, AND THE USE THEREOF FOR TREATING DIABETES | MERCK PATENT GmbH (DE) | 2004-10-06 | — | — | EP | claimed |
| EP-1450780-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF INFLAMMATION | MERCK PATENT GmbH (DE) | 2004-09-01 | — | — | EP | claimed |
| EP-1448181-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF METFORMIN AND A 4-OXOBUTANOIC ACID, AND THE USE THEREOF FOR TREATING DIABETES | MERCK PATENT GmbH (DE) | 2004-08-25 | — | — | EP | claimed |
| WO-2003057216-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLITAZONE AND A 4-OXOBUTANOIC ACID, AND THE USE THEREOF FOR TREATING DIABETES | MERCK PATENT GMBH (DE) | 2003-07-17 | — | — | WO | claimed |
| WO-2003047574-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A DERIVATIVE OF 5-PHENOXYALKYL-2,4-THIAZOLIDINEDIONE TYPE AND A 4-OXOBUTANOIC ACID | MERCK PATENT GMBH (DE) | 2003-06-12 | — | — | WO | claimed |
| WO-2003047561-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF INFLAMMATION | MERCK PATENT GMBH (DE) | 2003-06-12 | — | — | WO | claimed |
| WO-2003045368-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF METFORMIN AND A 4-OXOBUTANOIC ACID, AND THE USE THEREOF FOR TREATING DIABETES | MERCK PATENT GMBH (DE) | 2003-06-05 | — | — | WO | claimed |
| EP-0925273-B1 | PHARMACEUTICAL COMPOSITION CONTAINING 4-OXO-BUTYNIC ACIDS | MERCK PATENT GMBH (DE) | 2001-11-07 | — | — | EP | claimed |
| US-6143787-A | HETEROCYCLIC OR AROMATIC OXOACIDS | MERCK PATENT GESELLSCHAFT MIT (DE) | 2000-11-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273872-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH IMMUNOLOGICAL DISORDERS | ABAT, HOGA1, IL4I1 | KMO 524/4885CPA1 1841/4885CPA3 807/4885 |
| US-20050070553-A1 | Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes | GANAB, GAA, GANC | KMO 1642/4885CPA1 376/4885CPA3 565/4885 |
| US-20050014768-A1 | Use of 4-oxobutanoic acid derivatives in the treatment of inflammation | IL1B, HCAR2, IL6 | KMO 464/4885CPA1 1229/4885CPA3 605/4885 |
| US-20050085489-A1 | Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes | SLC5A1, DPP4, SLC5A2 | KMO 754/4885CPA1 1658/4885CPA3 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.